JP2021502415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502415A5 JP2021502415A5 JP2020544367A JP2020544367A JP2021502415A5 JP 2021502415 A5 JP2021502415 A5 JP 2021502415A5 JP 2020544367 A JP2020544367 A JP 2020544367A JP 2020544367 A JP2020544367 A JP 2020544367A JP 2021502415 A5 JP2021502415 A5 JP 2021502415A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination according
- administered
- riboceranib
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002955 immunomodulating agent Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 229960000106 biosimilars Drugs 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000013170 computed tomography imaging Methods 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024063774A JP2024095791A (ja) | 2017-11-10 | 2024-04-11 | 癌の処置のためのアパチニブを用いる併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584547P | 2017-11-10 | 2017-11-10 | |
| US62/584,547 | 2017-11-10 | ||
| PCT/US2018/060179 WO2019094832A1 (en) | 2017-11-10 | 2018-11-09 | A combination therapy with apatinib for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024063774A Division JP2024095791A (ja) | 2017-11-10 | 2024-04-11 | 癌の処置のためのアパチニブを用いる併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021502415A JP2021502415A (ja) | 2021-01-28 |
| JP2021502415A5 true JP2021502415A5 (enExample) | 2021-12-16 |
Family
ID=66439039
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544367A Pending JP2021502415A (ja) | 2017-11-10 | 2018-11-09 | 癌の処置のためのアパチニブを用いる併用療法 |
| JP2024063774A Withdrawn JP2024095791A (ja) | 2017-11-10 | 2024-04-11 | 癌の処置のためのアパチニブを用いる併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024063774A Withdrawn JP2024095791A (ja) | 2017-11-10 | 2024-04-11 | 癌の処置のためのアパチニブを用いる併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200282052A1 (enExample) |
| EP (1) | EP3706746A4 (enExample) |
| JP (2) | JP2021502415A (enExample) |
| KR (1) | KR20200107934A (enExample) |
| CA (1) | CA3082095A1 (enExample) |
| WO (1) | WO2019094832A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106176757B (zh) * | 2015-05-25 | 2019-12-10 | 江苏恒瑞医药股份有限公司 | 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途 |
| US20220387404A1 (en) * | 2019-09-11 | 2022-12-08 | Beigene, Ltd. | Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor |
| CN112741905A (zh) * | 2019-10-30 | 2021-05-04 | 江苏恒瑞医药股份有限公司 | Vegfr抑制剂与抗pd-1抗体联合在制备治疗妊娠滋养细胞肿瘤的药物中的用途 |
| US20230181593A1 (en) * | 2020-05-21 | 2023-06-15 | The Regents Of The University Of California | Compositions and methods for treating breast cancer |
| CN111558044B (zh) * | 2020-06-01 | 2022-02-11 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种包含舒尼替尼的药物组合物及其制剂和应用 |
| WO2024129903A1 (en) * | 2022-12-13 | 2024-06-20 | Elevar Therapeutics, Inc. | Pharmaceutical formulations of a tyrosine kinase inhibitor |
| WO2024130026A1 (en) * | 2022-12-16 | 2024-06-20 | Elevar Therapeutics, Inc. | Methods and compositions for treatment of subjects with hepatic impairments |
| WO2025024564A1 (en) * | 2023-07-24 | 2025-01-30 | The Board Of Regents Of The University Of Texas System | Small molecules that prevent statin-induced accumulation of hmg coa reductase |
| WO2025049528A1 (en) * | 2023-08-29 | 2025-03-06 | Cullinan Amber Corp. | Combination therapies for cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101676267B (zh) * | 2008-09-16 | 2012-12-26 | 江苏恒瑞医药股份有限公司 | N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 |
| KR20170060042A (ko) * | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| KR102662228B1 (ko) * | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CN106963948A (zh) * | 2017-05-12 | 2017-07-21 | 顾艳宏 | 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用 |
-
2018
- 2018-11-09 US US16/762,881 patent/US20200282052A1/en not_active Abandoned
- 2018-11-09 KR KR1020207016475A patent/KR20200107934A/ko not_active Ceased
- 2018-11-09 WO PCT/US2018/060179 patent/WO2019094832A1/en not_active Ceased
- 2018-11-09 EP EP18876849.3A patent/EP3706746A4/en active Pending
- 2018-11-09 CA CA3082095A patent/CA3082095A1/en active Pending
- 2018-11-09 JP JP2020544367A patent/JP2021502415A/ja active Pending
-
2024
- 2024-04-11 JP JP2024063774A patent/JP2024095791A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502415A5 (enExample) | ||
| CN110730663A (zh) | 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| Zhang et al. | Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study | |
| Xue et al. | Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer | |
| R Bernstein et al. | Hepatocellular carcinoma detection by gallium scan and subsequent treatment by gallium maltolate: rationale and case study | |
| CN115429883A (zh) | 用于联合治疗的抗肿瘤药物组合物 | |
| Mochizuki et al. | Metastatic gastric adenocarcinoma of the tongue with initial symptoms of glossodynia | |
| Xu et al. | Clinical efficacy of PD-1 inhibitor combined with radiotherapy in a multi-drug resistant patient with liver metastasis from gastric cancer | |
| Spigel et al. | Phase II trial of vinflunine in relapsed small cell lung cancer | |
| Di Lorenzo et al. | Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study | |
| Miglietta et al. | Chemotherapy with cisplatin and 5-fluorouracil chronomodulated infusion in locally advanced or metastatic/recurrent carcinoma of the cervix | |
| Xiang et al. | The combination of Tislelizumab and apatinib obtained complete remission for alpha-fetoprotein-producing gastric cancer with microsatellite stability: case report | |
| Isoyama et al. | Carboplatin and etoposide combined with radiotherapy for limited-stage small-cell esophageal carcinoma: three cases and review of the literature | |
| Nguyen et al. | PET-CT post–hepatic radiation changes in gastroesophageal adenocarcinoma | |
| Rineer et al. | Small cell carcinoma of the breast | |
| Mao et al. | Effect of anlotinib combined with ticeorgio for recurrent nasopharyngeal carcinoma: a case report | |
| Sahoo Sr et al. | Metastasis to breast from carcinoma gallbladder: a case report and review of literature | |
| Lee et al. | Pancreatic Cancer with Brain Metastases: Case Report with Literature Review. | |
| Gupta | Weekly paclitaxel in escalating doses in a patient with anthracycline-resistant, triple-negative, metastatic breast cancer with severe liver dysfunction | |
| Zhao et al. | 133TiP An open label pilot study to evaluate efficacy and safety of durvalumab with hepatic artery infusion chemotherapy (HAIC) in advanced hepatocellular (aHCC) patients with severe portal vein tumor thrombosis (PVTT)(Vp3 and/or Vp4): DurHope | |
| Rawat et al. | Efficacy and Safety of Erlotinib Addition to Concurrent Chemoradiation in Patients of Unresectable Esophageal Carcinoma: a Comparative Study | |
| Rosati et al. | Isolated Kidney Metastases from Rectal Cancer: Report of an Unusual Pattern of Recurrence | |
| Yang et al. | 56P Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study | |
| Thomas et al. | Bevacizumab with Paclitaxel and Carboplatin as Neo Adjuvant Chemotherapy for Stage 4 Ovarian Cancer-Case Report | |
| KR20240133986A (ko) | 항체 내면체성 메탈로풀러렌 접합체 및 그의 용도 |